- Home
- ADXN vs CDT Comparison
ADXN vs CDT Comparison
Compare ADXN & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADXN
- CDT
- Stock Information
- Founded
- ADXN 2002
- CDT 2019
- Country
- ADXN Switzerland
- CDT United States
- Employees
- ADXN N/A
- CDT N/A
- Industry
- ADXN Biotechnology: Pharmaceutical Preparations
- CDT Biotechnology: Pharmaceutical Preparations
- Sector
- ADXN Health Care
- CDT Health Care
- Exchange
- ADXN Nasdaq
- CDT Nasdaq
- Market Cap
- ADXN 11.3M
- CDT 10.9M
- IPO Year
- ADXN N/A
- CDT N/A
- Fundamental
- Price
- ADXN $7.80
- CDT $0.09
- Analyst Decision
- ADXN Strong Buy
- CDT
- Analyst Count
- ADXN 1
- CDT 0
- Target Price
- ADXN $30.00
- CDT N/A
- AVG Volume (30 Days)
- ADXN 56.3K
- CDT 14.6M
- Earning Date
- ADXN 11-22-2024
- CDT 11-26-2024
- Dividend Yield
- ADXN N/A
- CDT N/A
- EPS Growth
- ADXN N/A
- CDT N/A
- EPS
- ADXN 0.05
- CDT N/A
- Revenue
- ADXN $960,641.00
- CDT N/A
- Revenue This Year
- ADXN N/A
- CDT N/A
- Revenue Next Year
- ADXN N/A
- CDT N/A
- P/E Ratio
- ADXN $1.44
- CDT N/A
- Revenue Growth
- ADXN N/A
- CDT N/A
- 52 Week Low
- ADXN $5.00
- CDT $0.08
- 52 Week High
- ADXN $27.90
- CDT $7.83
- Technical
- Relative Strength Index (RSI)
- ADXN 31.62
- CDT 39.66
- Support Level
- ADXN $7.86
- CDT $0.09
- Resistance Level
- ADXN $9.89
- CDT $0.11
- Average True Range (ATR)
- ADXN 0.93
- CDT 0.01
- MACD
- ADXN -0.35
- CDT 0.00
- Stochastic Oscillator
- ADXN 4.57
- CDT 21.54
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment which is the discovery, development and commercialization of small-molecule pharmaceutical products.
About CDT Conduit Pharmaceuticals Inc.
Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being, prioritized by leading biopharmaceutical companies in order to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready in autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.